Lue, Nicholas Z. http://orcid.org/0000-0002-4236-9127
Garcia, Emma M.
Ngan, Kevin C. http://orcid.org/0000-0001-8067-3472
Lee, Ceejay
Doench, John G. http://orcid.org/0000-0002-3707-9889
Liau, Brian B. http://orcid.org/0000-0002-2985-462X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1DP2GM137494, 1DP2GM137494, 1DP2GM137494, 1DP2GM137494, 1DP2GM137494)
Damon Runyon Cancer Research Foundation (DDR 60S-20, DDR 60S-20, DDR 60S-20, DDR 60S-20, DDR 60S-20)
Harvard University (N/A, N/A, N/A, N/A, N/A)
National Science Foundation (DGE1745303, DGE1745303, DGE1745303)
Landry Cancer Biology Consortium
Herchel Smith Graduate Fellowship Program
Landry Cancer Biology Consortium, Herchel Smith Graduate Fellowship Program
Article History
Received: 12 April 2022
Accepted: 8 September 2022
First Online: 20 October 2022
Competing interests
: B.B.L. is on the scientific advisory board of H3 Biomedicine, holds a sponsored research project with H3 Biomedicine, is a scientific consultant for Imago BioSciences and is a shareholder and member of the scientific advisory board of Light Horse Therapeutics. J.G.D. consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo and Pfizer. J.G.D. consults for and has equity in Tango Therapeutics. J.G.D. serves as a paid scientific advisor to the Laboratory for Genomics Research, funded in part by GlaxoSmithKline. J.G.D. receives funding support from the Functional Genomics Consortium: Abbvie, Bristol Myers Squibb, Janssen, Merck and Vir Biotechnology. J.G.D.’s interests were reviewed and are managed by the Broad Institute in accordance with its conflict of interest policies. The remaining authors declare no competing interests.